Research Paper Volume 13, Issue 5 pp 6982—6998

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment

Zeta55 inhibits tumor growth in a CRPC xenograft model. (A) Percentage change in individual tumor volume of NOD-SCID mice with subcutaneous tumor xenograft grown from VCaP cells. NOD-SCID mice were castrated when the tumor volumes reached about 250mm3 on 63 days after subcutaneous injection of VCaP cells. After 21 days when the xenografts continued to grow, the castrated mice were treated with daily oral Zeta55 (30 mg/kg or 60 mg/kg) or MDV3100 (30 mg/kg) for 49 days (n=6). Tumor sizes were monitored twice a week after treatment. (B) Mean tumor volumes (mm3, +SEM) of NOD-SCID mice after treatment. (C) Mean body weight (g, +SEM) of NOD-SCID mice after treatment. *, P

Figure 4. Zeta55 inhibits tumor growth in a CRPC xenograft model. (A) Percentage change in individual tumor volume of NOD-SCID mice with subcutaneous tumor xenograft grown from VCaP cells. NOD-SCID mice were castrated when the tumor volumes reached about 250mm3 on 63 days after subcutaneous injection of VCaP cells. After 21 days when the xenografts continued to grow, the castrated mice were treated with daily oral Zeta55 (30 mg/kg or 60 mg/kg) or MDV3100 (30 mg/kg) for 49 days (n=6). Tumor sizes were monitored twice a week after treatment. (B) Mean tumor volumes (mm3, +SEM) of NOD-SCID mice after treatment. (C) Mean body weight (g, +SEM) of NOD-SCID mice after treatment. *, P < 0.01 vs. vehicle.